tm logo
HYLIBRIV
REGISTERED

on 05 Jul 2024

Last Applicant/ Owned by

GLAXO GROUP LIMITED

GSK Medicines Research CentreGunnels Wood Road, Stevenage SG1 2NY

GB

Serial Number

2226827 filed on 18th Oct 2022

Registration Number

TMA1243338 registered on 05th Jul 2024

Registration expiry Date

18th Oct 2032

Correspondent Address

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

HYLIBRIV

Trademark usage description

pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficien Read More

Classification Information


Class [005]
Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and Leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders.


Classification kind code

11

Mark Details


Serial Number

2226827

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 26
on 25th Mar 2024
Approved
Submitted for opposition 22
on 19th Mar 2024
Search Recorded
Submitted for opposition 256
on 09th Oct 2023
Notification of Possible Opposition Sent
Submitted for opposition 135
on 27th Jul 2023
Amendment to Application
Submitted for opposition 48
on 11th Jan 2023
Agent Changed
Submitted for opposition 257
on 08th Dec 2022
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 07th Dec 2022
Created
Submitted for opposition 31
on 07th Dec 2022
Formalized
Submitted for opposition 228
on 18th Oct 2022
International Registration
Submitted for opposition 30
on 18th Oct 2022
Filed